Pascal Biosciences Announces Formation of Clinical Advisory Board Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, May 8, 2019 – Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 23, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today provided a corporate update for the first quarter of 2019. “We’ve made significant strides since…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, April 1, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced that Carl Weissman has joined the company in the role of acting President. Weissman…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, March 18, 2019 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced a partnership with Mitacs for a multi-year cancer research project at the University of…
Read MoreAn interview with Dr. Patrick Gray, CEO of Pascal Biosciences, is featured in the latest episode of Cultivate – a news webcast distributed by CannabisTech.com, an online publication covering science and technology news in the cannabis and tech industries. We invite you to…
Read MoreVANCOUVER, British Columbia, and SEATTLE, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the testing of cannabinoids in human subjects for its immune stimulatory program in cancer. Furthermore,…
Read More- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic - Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development…
Read MoreAdvancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug…
Read MoreVANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, November 28, 2018 – Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the strengthening of its leadership team with the appointments of seasoned executives in therapeutic…
Read MoreListen to an interview with CEO Patrick Gray on Canada Pot Talks. Canada Pot Talks - November 10th 2018
Read More